300 million yuan!

As the core resource of the medical ecological supply side, the medical device industry is receiving strong support from national policies for its development under technological changes
.
Based on this, the development of China's medical device industry has also begun to enter the fast lane in recent years
.
Among them, it is worth noting that while China's medical device market continues to expand, many companies have also begun to increase their layout in this field
.
Recently, Broad Pharmaceuticals announced that the company and InnovHeart Srl ("InnovHeart") have reached an equity investment and product introduction strategic cooperation agreement.
Broad Pharmaceuticals will obtain approximately 17.
8% of InnovHeart's equity for approximately 43.
8 million euros (equivalent to 317 million yuan).
And the exclusive development, production and commercialization rights of Saturn, a global innovative medical device for mitral valve replacement, in China
.
Broad Pharmaceutical said that the mitral valve replacement product Saturn obtained this time will improve the company's layout in the field of structural heart disease, enrich the company's pipeline of products under research in the field of vascular intervention, and further promote the company's "passive + active" innovation The comprehensive establishment of the equipment platform
.
In addition to Yuanda Pharmaceuticals, many companies are also increasing their layout in the field of innovative medical devices
.
Prior to this, Baolight also stated that it would spend 30 million yuan to establish a medical device innovation research institute
.
Specifically, on November 22, Baolight issued an announcement stating that the company intends to establish a wholly-owned subsidiary, Guangdong Baolight High-end Medical Device Innovation Research Institute Co.
, Ltd.
Research Institute”)
.
The registered capital of the Innovation Research Institute is planned to be 30 million yuan.
After the completion of this investment, Baolight will hold 100% of the shares of the Innovation Research Institute
.
In addition, Blue Sail Medical also chose to invest in OCT (Optical Coherence Tomography) company Nanjing Wolfman in order to further expand the business layout of cardio-cerebrovascular medical equipment and enrich its product portfolio in the field of coronary intervention
.
It is reported that OCT imaging can accurately guide PCI (percutaneous coronary intervention) surgery
.
In the past, Blue Sail Medical's products in the cardiovascular field were mainly focused on treatment.
After investing in Wolfman, it will graft Wolfman's new diagnostic technology on the existing sales platform in the cardiovascular field
.
For some companies to accelerate the introduction of innovative medical devices and investment in innovative medical device companies, the industry believes that this may be due to the obvious differences in the subdivision of medical devices.
If they cannot further expand their market share, fierce external competition will accelerate the elimination of some companies.

.
It is understood that in recent years, due to centralized procurement and other reasons, the threshold for the medical device industry is further increasing, and this is also forcing companies to accelerate innovation and transformation
.
In the future, under the background of mass procurement and the two-invoice system, the industry predicts that higher requirements will be imposed on the capital, brand, and financing costs of enterprises, and this will affect the innovative strength and innovation differentiation level of medical device companies.
There will be more and more tests
.
This requires domestic medical device companies not to stay in the imitation stage, to have forward-looking thinking and strategic vision, as well as independent research and development, innovation and development capabilities, to continuously break new technologies and meet higher market demands
.